| 排名 | 分析师 | 机构 | 行业 | 年度收益率 | 6个月收益率 | 3个月收益率 | 正收益比例 | 成分股数量 | 历史最大跌幅 | 更新日期 |
|---|---|---|---|---|---|---|---|---|---|---|
| 1 | 夏禹 | 国联民生 | 医药生物 | 51.69% | 46.44% | 35.81% | 20.00% | 7 | -52.01% | 2025-06-04 |
| 2 | 胡晨曦 | 长城国瑞证券 | 医药生物 | 51.68% | 50.43% | 47.93% | 12.50% | 6 | -27.10% | 2025-05-07 |
| 3 | 李安飞 | 广发证券 | 医药生物 | 51.64% | 44.50% | 46.59% | -2.86% | 1 | -56.96% | 2025-04-21 |
| 4 | 夏禹 | 国联民生 | 医药生物 | 51.59% | 24.43% | -3.18% | 20.00% | 7 | -52.01% | 2025-10-20 |
| 5 | 年庆功 | 国海证券 | 医药生物 | 51.57% | 56.90% | 41.80% | -25.00% | 8 | -18.14% | 2025-08-25 |
| 6 | 李安飞 | 广发证券 | 医药生物 | 51.57% | 38.00% | 28.68% | -2.86% | 1 | -56.96% | 2025-06-05 |
| 7 | 王道 | 申万宏源 | 医药生物 | 51.56% | 51.46% | 42.55% | 33.33% | 4 | -42.73% | 2025-09-05 |
| 8 | 李安飞 | 广发证券 | 医药生物 | 51.52% | 43.72% | 46.38% | -2.86% | 1 | -56.96% | 2025-04-22 |
| 9 | 夏禹 | 国联民生 | 医药生物 | 51.50% | 49.48% | 21.70% | 20.00% | 7 | -52.01% | 2025-08-11 |
| 10 | 唐寅灏 | 中信证券 | 医药生物 | 51.50% | 44.39% | 35.20% | 85.71% | 12 | -8.47% | 2025-06-16 |
| 11 | 王道 | 申万宏源 | 医药生物 | 51.47% | 49.98% | 42.78% | 33.33% | 4 | -42.73% | 2025-09-02 |
| 12 | 周豫 | 太平洋 | 医药生物 | 51.46% | 40.79% | 33.98% | 21.21% | 23 | -55.62% | 2025-08-21 |
| 13 | 周豫 | 太平洋 | 医药生物 | 51.44% | 40.76% | 34.54% | 21.21% | 23 | -55.62% | 2025-08-22 |
| 14 | 顾资然 | 中信证券 | 医药生物 | 51.41% | 44.01% | 28.87% | 66.67% | 6 | -1.79% | 2025-10-20 |
| 15 | 胡晨曦 | 长城国瑞证券 | 医药生物 | 51.41% | 50.66% | 47.67% | 12.50% | 6 | -27.10% | 2025-05-08 |
| 16 | 年庆功 | 国海证券 | 医药生物 | 51.38% | 53.69% | 42.04% | -25.00% | 7 | -18.14% | 2025-08-21 |
| 17 | 赵海春 | 国金证券 | 医药生物 | 51.36% | 56.93% | 63.44% | -25.00% | 2 | -61.07% | 2025-07-07 |
| 18 | 胡晨曦 | 长城国瑞证券 | 医药生物 | 51.31% | 50.56% | 47.58% | 12.50% | 6 | -27.10% | 2025-05-09 |
| 19 | 周豫 | 太平洋 | 医药生物 | 51.28% | 39.78% | 20.00% | 21.21% | 23 | -55.62% | 2025-09-09 |
| 20 | 仰佳佳 | 申万宏源 | 医药生物 | 51.19% | 41.82% | 15.26% | 23.08% | 3 | -37.64% | 2025-09-04 |